Evidence map›Paper›PMID 41165545›Full record

ArticleJournal of the International Neuropsychological Society : JINS2025

Development and validation of the TabCAT-EXAMINER: A tablet-based executive functioning battery for research and clinical trials.

Mark Sanderson-Cimino, Katherine L Possin, Dan M Mungas, Emily W Paolillo, Breton M Asken, Elena Tsoy, Sabrina Jarrott, Yann Cobigo, Rowan Saloner, Kaitlin B Casaletto and 21 more

Abstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the International Neuropsychological Society : JINS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Mark Sanderson-CiminoMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5872-3186
Katherine L PossinMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Dan M MungasGlobal Brain Health Institute, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-2035-7085
Emily W PaolilloMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Breton M AskenFlorida Alzheimer's Disease Research Center, Department of Clinical and Health Psychology, University of Florida, Gainesville, Florida, USA.
Elena TsoyMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Sabrina JarrottMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Yann CobigoMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Rowan SalonerMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Kaitlin B CasalettoMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Ciaran ConsidineDepartment of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Julie A FieldsDepartment of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-1282-9866
Joie MoldenDepartment of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Aurora, CO, USA.
Katya RascovskyDepartment of Neurology and Penn Frontotemporal Degeneration Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Sandra WeintraubMesulam Center for Cognitive Neurology and Alzheimer's Disease, Department of Neurology, Northwestern University, Chicago, IL, USA.
Bonnie WongDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Hilary W HeuerMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Leah K ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Julio C RojasMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Lawren VandeVredeMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Peter LjubenkovMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Gil D RabinoviciMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Maria Luisa Gorno-TempiniMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
William W SeeleyMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Bruce L MillerMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Bradley F BoeveMesulam Center for Cognitive Neurology and Alzheimer's Disease, Department of Neurology, Northwestern University, Chicago, IL, USA.
Howard J RosenMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Adam L BoxerMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Katherine P RankinMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Joel H KramerMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Adam M StaffaroniMemory and Aging Center, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$120.9M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
The Frontotemporal Lobar Degeneration Neuroimaging InitiativeR01AG032306 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSEN, HOWARD J · 2009 to 2013
$10.0M
Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
NIA NIH HHS K23 AG061253NIA NIH HHS K23 AG090757NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG048234NIA NIH HHS R01 AG058233NIA NIH HHS R01 AG071756NIA NIH HHS R01 AG073482NIA NIH HHS R01 AG077557NIA NIH HHS RF1 AG032289NIA NIH HHS RF1 AG077557NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NINDS NIH HHS R01 NS050915NINDS NIH HHS R56 NS050915NINDS NIH HHS RF1 NS050915NINDS NIH HHS U01 NS128913NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

objectiveThe National Institutes of Health (NIH) Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (EXAMINER) is a validated laptop-based battery of executive functioning tests. A modified tablet version of the EXAMINER was developed on the UCSF Tablet-based Cognitive Assessment Tool (TabCAT-EXAMINER). Here we describe the battery and investigate the reliability and validity of a composite score.

methodsA diagnostically heterogeneous sample of 2135 individuals (mean age = 65.58, SD = 16.07), including controls and participants with a variety of neurodegenerative syndromes, completed the TabCAT-EXAMINER. A composite score was developed using confirmatory factor analysis and item response theory. Validity was evaluated via linear regressions that tested associations with neuropsychological tests, demographics, clinical diagnosis, and disease severity. Replicability of cross-sectional results was tested in a separate sample of participants (

resultsThe TabCAT-EXAMINER score was normally distributed, demonstrated high test-retest reliability, and was associated in the expected directions with independent tests of executive functioning, demographics, disease severity, and diagnosis. Greater baseline disease severity was associated with more rapid longitudinal TabCAT-EXAMINER decline.

conclusionsThe TabCAT-EXAMINER is a tablet-based executive functioning battery developed for observational research and clinical trials. Performance can be summarized as a single composite score, and results of this study support its reliability and validity in cognitive aging and neurodegenerative disease cohorts.

Indexed as

Cognitive DysfunctionComputers, HandheldExecutive FunctionNeurodegenerative DiseasesNeuropsychological TestsAgedAged, 80 and overClinical Trials as TopicCross-Sectional StudiesFactor Analysis, StatisticalFemaleHumansMaleMiddle AgedPsychometricsReproducibility of ResultsAlzheimer’s diseasecomputerized cognitive assessmentdigitalfrontotemporal dementiaNeuropsychology

Identifiers

PMID41165545
PMCPMC12810153

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.